Navigation Links
Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
Date:4/15/2008

- New Approach to Targeting the Tumor Microenvironment -

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new pre-clinical findings on the treatment of prostate cancer models at the American Association for Cancer Research (AACR) conference. Halozyme is investigating its Pegylated-rHuPH20 enzyme (PEGrHuPH20) as a candidate for the systemic treatment of tumors rich in hyaluronan (HA) in combination with chemotherapy.

The studies explored the physiologic responses to enzymatic removal of HA-based matrices surrounding tumor cells in the tumor microenvironment of prostate tumors following systemic administration of its PEGrHuPH20 pre-clinical candidate. In animal pharmacokinetic models, PEGrHuPH20 demonstrated a more than 2,000-fold increase in plasma half-life compared to the unmodified enzyme. Prostate tumors were grown around the bone as a model of elevated interstitial fluid pressure (IFP). Treatment commenced when tumors had reached approximately 500 mm3 in size and pressure within the tumor had reached 30-40 mm Hg.

The objectives of these studies were to determine whether HA-dependent pericellular matrices produced in vitro and in vivo by hormone refractory prostate cancer cell line could be enzymatically depleted in prostate carcinoma xenografts following intravenous (IV) administration of the PEGrHuPH20 enzyme. The dose dependent effects of systemic enzyme treatment were evaluated by a combination of direct micropressure measurements, magnetic resonance imaging (MRI), ultrasound, immunohistochemistry, and determination of tumor water content. A summa
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
2. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... , July 24, 2014 Decision Resources Group ... the EU5 countries ( France , ... Spain and the ... of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) ... uptake of Relvar as a first-line LABA/ICS FDC in ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Calif., Nov. 17 Poniard Pharmaceuticals, Inc. (Nasdaq: ... randomized, controlled Phase 2 trial of picoplatin in patients ... indicated that picoplatin, given once every four weeks in ... has comparable efficacy to oxaliplatin, given in combination with ...
... , LAKE ZURICH, Ill., Nov. 17 ... improving blood collection, separation, safety and availability, announced today ... the Verax Platelet PGD® test as a quality control ... platelets prior to transfusion. Fenwal is the exclusive ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 2FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 4
(Date:7/24/2014)... 24, 2014 Just as fitness and ... consider their own financial and marketing strength to be ... campaigns to the next level by using the most ... IVR, Voice Broadcast, Call Tracking and SMS texting ... rate, text messages are quickly become integral in marketing ...
(Date:7/24/2014)... CarePoint Health is proud to ... oncology, Dr. Hitendra Upadhyaya, has joined our network, ... Upadhyaya to the community. Hundreds of highly skilled ... a comprehensive network of top doctors and practices ... specialties. This latest acquisition represents CarePoint Health’s commitment ...
(Date:7/24/2014)... of Medicine researchers may have found a way to ... that pre-treatment of neurons with the anti-aging protein Klotho ... toxic amyloid protein and glutamate. These findings currently appear ... , Alzheimer,s disease is the most frequent age-related dementia ... age 65 and older and more than 40 percent ...
(Date:7/24/2014)... -- Drinking caffeine may worsen the hot flashes and ... they go through menopause, new survey data suggests. ... limiting caffeine intake may be useful for those postmenopausal ... said researcher Dr. Stephanie Faubion, director of the Women,s ... But caffeine -- a stimulant found in coffee ...
(Date:7/24/2014)... Bonheur Children,s Hospital and the University of Tennessee Health ... a new drug shown to safely reduce the viral ... infected with respiratory syncytial virus (RSV). RSV is the ... young children in the United States and worldwide. ... Disease Specialist John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:RSV research breakthrough to help infected children 2
... Studies/Tests; Cover-up Health Hazards on Illinois Beaches ... Beach Visitors, Asbestos Safety Tips Published, CHICAGO, ... send, the media and public are advised to use ... Illinois Dunesland Preservation,Society asked nationally recognized asbestos safety risk ...
... & Amy Philo*, SAN DIEGO, May 23 ... Day, May 10, 1998, Sharon Alley stabbed her ... her. Months before, Alley,was prescribed Paxil, became psychotic, ... her skull., Postpartum Support International (PSI) founder ...
... Two-dozen members,of the Army,s 2nd Battalion, 113th ... LaserVision, getting ready for their upcoming,deployment in Iraq. ... were,undergoing a Lasik procedure that allows them to ... http://www.newscom.com/cgi-bin/prnh/20080523/NYF043 ), Drs. Joseph and Jeffery ...
... into Chengdu, STAMFORD, Conn., May 23 The ... private organizations left,Kansas City today, and AmeriCares medicines and ... is proud to play an instrumental,role in delivering critical ... many years for the people, infrastructure and landscape,of China ...
... 2008 A recent study shows that pre-operative assessments of ... early diagnosis and successful treatment of lymphedema. , The ... and the National Institutes of Health (NIH) and in ... University, was published in the journal, Cancer (April 25, ...
... COMMIT LOZENGE CAN HELP REVERSE MENTAL ACUITY DEFICITS ... for Interview to Address FAA,Ruling on Smoking Cessation ... by the Federal Aviation,Administration (FAA) that it has ... of safe medications for pilots and air-traffic,controllers, it,s ...
Cached Medicine News:Health News:UPDATED: Deadly Asbestos Fibers Found on Chicago's Oak Street Beach 2Health News:UPDATED: Deadly Asbestos Fibers Found on Chicago's Oak Street Beach 3Health News:The MOTHERS Act: Thalidomide Revisited? 2Health News:The MOTHERS Act: Thalidomide Revisited? 3Health News:The MOTHERS Act: Thalidomide Revisited? 4Health News:Soldiers Receive Free Memorial Day Lasik Surgery Before Going to Iraq 2Health News:AmeriCares Ships Medicines and Medical Supplies to Earthquake Victims in China 2Health News:New study shows positive role physical therapists play in lymphedema diagnois and treatment 2Health News:MultiVu Video Feed: FREE NICOTINE REPLACEMENT THERAPY (NRT) TO BE OFFERED TO REGISTERED PILOTS INTERESTED IN QUITTING RELIEF IN LIGHT OF RECENT FAA RULINGS 2
... The THERMOstar is a high performance temperature ... microplates. Temperature, shaking speed and incubation time ... the status parameters are displayed on the ... above and below the microplates provide uniform ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9 Broth...
An agent used for making solid microbiological media....
Medicine Products: